BioSpace News Archive

The FDA has granted Madorra breakthrough device designation for the company’s non-invasive, home-use device for a subset of women experiencing moderate to severe vulvovaginal atrophy (VVA), a component of genitourinary syndrome of menopause (GSM).

Ryvu Therapeutics (WSE: RVU) reported today its 2021 semiannual financial results and provided a corporate update.

Eyam Vaccine and Immunotherapeutics (EYAM), a next-generation vaccine biotechnology company, announced today an agreement with Veristat, a scientific-minded, global clinical research organization (CRO), to plan and coordinate clinical trials of their vaccine program against SARS-CoV-2.

SkinCure Oncology, today announced the results of a groundbreaking study that shows a 99.3 percent cure rate in treating basal cell carcinoma and squamous cell carcinoma with Image-Guided SRT.

ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), today announced a global licensing and research collaboration with Eli Lilly and Company (Lilly) focused on the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system.

TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced that President and CEO Glenn Mattes will present a corporate overview at 23rd H.C. Wainwright Annual Global Investment Conference.

Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS) and other diseases with significant unmet medical need, today announced the initiation of its NATiV3 Phase III clinical trial evaluating lanifibranor for the treatment of NASH.

Cytokinetics, Incorporated announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to participate in the following investor conferences in September.

Albireo Pharma, Inc., a rare pediatric liver disease company developing novel bile acid modulators, announced the grant of inducement stock options exercisable for an aggregate of 15,000 shares of Albireo’s common stock and restricted stock units representing the opportunity to acquire 3,500 shares of Albireo’s common stock.

Atreca, Inc., a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, announced that it will present at the following upcoming virtual investor conferences: